The New England Journal of Medicine has published findings from the ALLEGORY trial, examining whether adding obinutuzumab to standard treatment improves outcomes for adults with active lupus.
The New England Journal of Medicine (@NEJM) published details of the ALLEGORY trial in March 2026. The trial evaluated the efficacy and safety of obinutuzumab — a drug that targets specific immune cells — when added to the standard treatment already used for adults with active systemic lupus erythematosus (a long-term autoimmune condition, commonly known as lupus, in which the body’s immune system attacks healthy tissue).
The journal has made the full study available to read at no cost. According to the @NEJM post, a video summary created with @DGlaucomflecken is intended to make the trial’s findings more accessible to a wider audience.
Lupus affects the immune system and can damage joints, skin, kidneys and other organs. Standard therapy exists, but researchers have been exploring whether obinutuzumab — already used in some blood cancer treatments — can offer additional benefit when layered on top of it.
The ALLEGORY trial specifically looked at adults with active disease, assessing both how well the combination worked and whether it was safe to use.
The trial randomised 303 patients. At week 52, an SRI-4 response occurred in 76.7% of the obinutuzumab group compared with 53.5% of the placebo group. Readers wanting to understand what the findings might mean for their own care should speak to their GP or specialist.
—
If you have concerns about a long-term condition, contact your GP or call NHS 111. In a medical emergency, dial 999.
Source: @NEJM